Article Text

Download PDFPDF
Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes
  1. P G Steg1,
  2. B Iung1,
  3. L J Feldman1,
  4. D Cokkinos3,
  5. J Deckers4,
  6. K A A Fox2,
  7. U Keil5,
  8. A P Maggioni6,
  9. For The Enact Investigators
  1. 1Groupe Hospitalier Bichat – Claude Bernard, Assistance Publique-Hôpitaux de Paris, Paris, France
  2. 2Cardiovascular Research, Department of Medical and Radiological Sciences, University of Edinburgh, Edinburgh, UK
  3. 3Cardiology Department, Onassis Cardiac Surgery Centre, Athens, Greece
  4. 4Cardialysis BV, Rotterdam, Netherlands
  5. 5Institut für Epidemiologie und Sozialmedizin, Universität Münster, D48149 Münster, Germany
  6. 6Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche, Milan, Italy
  1. Correspondence to:
    Dr Philippe Gabriel Steg, Cardiology, Hôpital Bichat, 46 rue Henri Huchard, 75877 Paris Cedex 18, France;
    gabriel.steg{at}bch.ap-hop-paris.fr

Abstract

Background: It has been suggested that patients undergoing acute intervention for coronary syndromes may not receive adequate secondary prevention.

Objective: To analyse the impact of availability and use of coronary interventions on the prescription of secondary prevention after acute coronary syndromes.

Design: Analysis of a prospective multicentre register of patients admitted to hospital for acute coronary syndromes.

Setting: A 1999 pan-European survey in 390 hospitals.

Patients: 3092 patients admitted to hospital with acute coronary syndromes (including 777 for ST elevation myocardial infarction within 12 hours of onset).

Main outcome measures: Rates of prescription of aspirin and lipid lowering agents.

Results: Performance of coronary angiography and percutaneous coronary interventions (PCI) during the hospital stay were independent predictors of prescription of aspirin at discharge (odds ratio (OR) 1.29 and 1.89, p = 0.053 and p < 0.0001, respectively). Lipid lowering agents were prescribed more often on discharge in patients admitted to hospitals with catheterisation laboratories than without (for infarction with ST elevation, 45% v 40% (NS); for other acute coronary syndromes, 46% v 36%; p < 0.05). Prescription rates were higher among patients undergoing coronary angiography or PCI than in those treated conservatively (for infarction with ST elevation, 49%, 53%, and 39%, p < 0.05; for other acute coronary syndromes, 50%, 54%, and 34%, p < 0.05). Logistic regression analysis showed that PCI was an independent predictor of prescription of lipid lowering agents at discharge (OR 1.48, p < 0.0002).

Conclusions: Contrary to expectations, invasive procedures for acute coronary syndromes are associated with higher rates of prescription of pharmacological secondary prevention.

  • acute coronary syndromes
  • aspirin
  • lipid lowering treatment
  • myocardial infarction
  • ACE, angiotensin converting enzyme
  • ENACT, European network for acute coronary treatment
  • HOPE, heart outcomes prevention trial
  • PCI, percutaneous coronary intervention

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes